CN115501138B - Bionic fetal fat composition, preparation method and application - Google Patents
Bionic fetal fat composition, preparation method and application Download PDFInfo
- Publication number
- CN115501138B CN115501138B CN202211142867.1A CN202211142867A CN115501138B CN 115501138 B CN115501138 B CN 115501138B CN 202211142867 A CN202211142867 A CN 202211142867A CN 115501138 B CN115501138 B CN 115501138B
- Authority
- CN
- China
- Prior art keywords
- phase
- parts
- stirring
- liquid
- bionic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000001605 fetal effect Effects 0.000 title claims abstract description 39
- 239000011664 nicotinic acid Substances 0.000 title claims abstract description 38
- 239000000203 mixture Substances 0.000 title claims abstract description 37
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 238000003756 stirring Methods 0.000 claims abstract description 70
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 30
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 28
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims abstract description 20
- 241000727169 Prinsepia utilis Species 0.000 claims abstract description 16
- 235000012000 cholesterol Nutrition 0.000 claims abstract description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 14
- 150000002632 lipids Chemical class 0.000 claims abstract description 12
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims abstract description 10
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims abstract description 10
- MVORZMQFXBLMHM-QWRGUYRKSA-N Gly-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 MVORZMQFXBLMHM-QWRGUYRKSA-N 0.000 claims abstract description 10
- ATGQXSBKTQANOH-UWVGARPKSA-N N-oleoylphytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@H](CO)NC(=O)CCCCCCC\C=C/CCCCCCCC ATGQXSBKTQANOH-UWVGARPKSA-N 0.000 claims abstract description 10
- 240000005546 Piper methysticum Species 0.000 claims abstract description 10
- 235000016787 Piper methysticum Nutrition 0.000 claims abstract description 10
- 229920002385 Sodium hyaluronate Polymers 0.000 claims abstract description 10
- 235000021355 Stearic acid Nutrition 0.000 claims abstract description 10
- 102000019197 Superoxide Dismutase Human genes 0.000 claims abstract description 10
- 108010012715 Superoxide dismutase Proteins 0.000 claims abstract description 10
- 235000013871 bee wax Nutrition 0.000 claims abstract description 10
- 239000012166 beeswax Substances 0.000 claims abstract description 10
- 229910052802 copper Inorganic materials 0.000 claims abstract description 10
- 239000010949 copper Substances 0.000 claims abstract description 10
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000008367 deionised water Substances 0.000 claims abstract description 10
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 10
- 238000000855 fermentation Methods 0.000 claims abstract description 10
- 230000004151 fermentation Effects 0.000 claims abstract description 10
- 239000006166 lysate Substances 0.000 claims abstract description 10
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims abstract description 10
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims abstract description 10
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims abstract description 10
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229940010747 sodium hyaluronate Drugs 0.000 claims abstract description 10
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims abstract description 10
- 229940032094 squalane Drugs 0.000 claims abstract description 10
- 239000008117 stearic acid Substances 0.000 claims abstract description 10
- 229960001295 tocopherol Drugs 0.000 claims abstract description 10
- 229930003799 tocopherol Natural products 0.000 claims abstract description 10
- 235000010384 tocopherol Nutrition 0.000 claims abstract description 10
- 239000011732 tocopherol Substances 0.000 claims abstract description 10
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 claims abstract description 10
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims abstract description 10
- 229940007061 capsicum extract Drugs 0.000 claims abstract description 9
- 239000001943 capsicum frutescens fruit extract Substances 0.000 claims abstract description 9
- 239000000654 additive Substances 0.000 claims abstract description 6
- 230000000996 additive effect Effects 0.000 claims abstract description 6
- 239000007788 liquid Substances 0.000 claims description 72
- 230000001804 emulsifying effect Effects 0.000 claims description 30
- 238000002156 mixing Methods 0.000 claims description 16
- 239000012530 fluid Substances 0.000 claims description 15
- 239000000463 material Substances 0.000 claims description 15
- 239000000243 solution Substances 0.000 claims description 15
- 238000005303 weighing Methods 0.000 claims description 15
- 238000010438 heat treatment Methods 0.000 claims description 12
- 239000002245 particle Substances 0.000 claims description 12
- 238000001816 cooling Methods 0.000 claims description 11
- 239000011259 mixed solution Substances 0.000 claims description 7
- 235000013529 tequila Nutrition 0.000 claims description 6
- 241000235346 Schizosaccharomyces Species 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 4
- 230000008591 skin barrier function Effects 0.000 abstract description 7
- 240000004246 Agave americana Species 0.000 abstract description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 abstract description 3
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 abstract 1
- 229940044176 ceramide 3 Drugs 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 38
- 239000012528 membrane Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 150000004665 fatty acids Chemical class 0.000 description 6
- 230000008439 repair process Effects 0.000 description 6
- 210000002374 sebum Anatomy 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 5
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 5
- 229940106189 ceramide Drugs 0.000 description 5
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000002537 cosmetic Substances 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 5
- 230000037394 skin elasticity Effects 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000265 homogenisation Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000019612 pigmentation Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000005808 skin problem Effects 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 241000208293 Capsicum Species 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 230000037365 barrier function of the epidermis Effects 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000001390 capsicum minimum Substances 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 230000006128 skin development Effects 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 210000004511 skin melanocyte Anatomy 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/66—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/68—Sphingolipids, e.g. ceramides, cerebrosides, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9728—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/805—Corresponding aspects not provided for by any of codes A61K2800/81 - A61K2800/95
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The bionic fetal fat composition disclosed by the invention consists of A, B, C three phases, wherein the A phase consists of hydrogenated lecithin, glycerol, biological glycogelatin-2, sodium hyaluronate and deionized water; the phase B comprises ceramide-3, cholesterol, beeswax, stearic acid, caprylic/capric triglyceride, squalane, prinsepia utilis royle oil and tocopherol; the phase C comprises superoxide dismutase, tripeptide-1 copper, kava extract, capsicum extract, agave praecox leaf extract, and fermentation lysate of Saccharomyces cerevisiae. The preparation method of the bionic fetal fat comprises the following steps: firstly, A, B, C three phases are prepared, the phase A and the phase B are respectively stirred, and then the phases A and B are mixed and stirred under vacuum; adding phase C, stirring, and delivering into a nanometer homogenizer for treatment after the solution is uniform. The invention also discloses application of the bionic fetal fat composition as a skin care product additive. The bionic fetal lipid composition disclosed by the invention can be used for repairing the skin barrier better and increasing the resistance of the skin.
Description
Technical Field
The invention belongs to the technical field of cosmetics, and particularly relates to a bionic fetal fat composition, a preparation method of the composition and application of the composition.
Background
Along with the use of electronic products in daily life, except sunlight, blue light can be released from an electronic screen, a fluorescent lamp and an LED lamp in the use process, and the blue light can cause long-term pigmentation by influencing skin melanocytes, so that the color deposition residue is more durable than UVB induction, and therefore, the damage of the blue light to skin health is not negligible, and in general, people can use skin care products to enable the skin care products to form a layer of film on the skin surface to slow down the damage of the blue light to the skin when resisting the blue light.
The fetal fat is a natural biological protective film covered on the surface of the fetal skin, can effectively isolate invasion of pollutants in the amniotic fluid alkaline environment, and has protection and promotion effects on fetal skin development. In recent years, research and development of composition, efficacy and simulation application of the vernix in China and abroad have found that the vernix has the effects of moisturizing, inhibiting bacteria, buffering pH, promoting the growth of skin epidermal barrier and the like, and can effectively slow down the damage of blue light to human skin. However, the natural fetid can not be directly used for preparing skin care products, so most of the existing fetid skin care products are prepared by adopting bionic fetid. Although the existing bionic cosmetic for the fetuses has good skin affinity, the problem of low resistance caused by poor effect of repairing skin barrier exists.
Disclosure of Invention
The invention aims to provide a bionic fetal fat composition which can better repair skin barriers and increase skin resistance.
The second purpose of the invention is to provide a preparation method of the bionic fetal fat composition, which effectively solves the problems that the existing bionic fetal fat cosmetics have large coating particle size and are difficult to pass through sebum membranes.
A third object of the present invention is to provide the use of the above bionic fetal lipid composition.
The first technical scheme adopted by the invention is that the bionic fetal fat composition consists of an A phase, a B phase and a C phase, wherein the A phase consists of the following components in parts by mass: 5 to 10 parts of hydrogenated lecithin, 5 to 20 parts of glycerol, 0.1 to 3 parts of biological sugar gum-2, 0.01 to 0.3 part of sodium hyaluronate and 13 to 83 parts of deionized water;
the phase B consists of the following components in parts by mass: 0.5 to 5 parts of ceramide NP, 0.1 to 3 parts of cholesterol, 0.5 to 5 parts of beeswax, 0.3 to 3 parts of stearic acid, 1 to 7 parts of caprylic/capric triglyceride, 1 to 5 parts of squalane, 0.5 to 7 parts of prinsepia utilis royle oil and 0.1 to 1 part of tocopherol;
the phase C consists of the following components in parts by mass: 0.005-0.1 part of superoxide dismutase, 0.0005-0.002 part of tripeptide-1 copper, 0.3-2.5 parts of kava extract, 0.5-4 parts of capsicum extract, 0.1-3 parts of tequila leaf extract and 2-8 parts of dipyrus fermentation lysate.
The first aspect of the present invention is also characterized in that,
the mass ratio among the phase A, the phase B and the phase C is that the phase A: and B phase: phase c=20 to 95:3.5 to 40:2.5 to 20.
The second technical scheme of the invention is that the preparation method of the bionic fetal fat composition comprises the following steps:
step 1, respectively weighing 5-10 parts of hydrogenated lecithin, 5-20 parts of glycerol, 0.1-3 parts of biological sugar gum-2, 0.01-0.3 part of sodium hyaluronate and 13-83 parts of deionized water according to parts by weight, and mixing and uniformly stirring the weighed material components to form a phase A;
according to the parts by weight, respectively weighing 0.5-5 parts of ceramide NP, 0.1-3 parts of cholesterol, 0.5-5 parts of beeswax, 0.3-3 parts of stearic acid, 1-7 parts of caprylic/capric triglyceride, 1-5 parts of squalane, 0.5-7 parts of prinsepia utilis royle oil and 0.1-1 part of tocopherol, mixing and uniformly stirring the weighed material components to form a phase B;
according to the parts by weight, respectively weighing 0.005-0.1 part of superoxide dismutase, 0.0005-0.002 part of tripeptide-1 copper, 0.3-2.5 parts of kava extract, 0.5-4 parts of capsicum extract, 0.1-3 parts of tequila leaf extract and 2-8 parts of schizosaccharomyces cerevisiae fermentation lysate, mixing and stirring the weighed material components uniformly to form a C phase;
the mass ratio among the phase A, the phase B and the phase C is the phase A: and B phase: c phase=20-95:3.5-40:2.5-20;
step 2, adding the phase A obtained in the step 1 into an emulsifying pot, and stirring until the liquid is granular or powder-free to precipitate and suspend, so that the phase A is completely dissolved; adding the phase B obtained in the step 1 into an oil phase pot, and stirring until the liquid is granular or powder-free to precipitate or suspend, so that the phase B is completely dissolved;
step 3, adding the phase B processed in the step 2 into the emulsifying pot for mixing when the phase A liquid in the emulsifying pot is homogenized in the step 2, homogenizing the mixed solution for 5-10 min in a vacuum state, stirring for 10-20 min, and cooling the mixed liquid;
and step 4, adding the phase C into an emulsifying pot, stirring for 20-30 min at a stirring speed of 20-40 r/min, and sending the mixture into a high-pressure fluid nanometer homogenizer for treatment after the mixture is completely uniform, thus obtaining the bionic fetal fat composition.
The second solution of the invention is also characterized in that,
and (2) stirring to dissolve the phase A substance, namely stirring the liquid in the pot at the rotating speed of 30-50 r/min, heating the liquid in the emulsifying pot to 80-85 ℃ at the same time, homogenizing for 2-5 min, adjusting the temperature of the liquid to 78-82 ℃, and continuously stirring at the rotating speed of 30-50 r/min for 10-15 min.
And (2) stirring to dissolve the B phase substance, namely stirring the liquid in the oil phase pot at the rotating speed of 30-50 r/min, heating the liquid in the oil phase pot to 80-85 ℃, maintaining the temperature of the liquid at 80-85 ℃, and continuing stirring at the rotating speed of 30-50 r/min for 10-30 min.
In the step 3, the stirring speed is 30 r/min-50 r/min, and the temperature of the solution is 40-50 ℃ after the temperature is reduced.
In the step 4, the high-pressure fluid nano homogenizer is specifically treated by setting the pressure of the high-pressure fluid nano homogenizer to 1100-1300 psi, and the solution is circularly treated for 6-10 times until the particle size is reduced by 7-10 times.
The third technical scheme of the invention is the application of the bionic fetal fat composition, and the application of the bionic fetal fat composition as a skin care product additive.
The invention has the advantages that,
(1) The bionic fetal lipid composition is prepared from the prinsepia utilis royle oil, the sebaceous membrane component ceramide, the cholesterol and the fatty acid, and the natural fatty acid content of the prinsepia utilis royle oil is balanced, so that the repairing effect of the skin barrier can be well enhanced by matching the prinsepia utilis royle oil with the sebaceous membrane component ceramide, the cholesterol and the fatty acid, and the resistance of the skin is enhanced.
(2) The bionic fetal lipid composition disclosed by the invention adopts a plurality of nutritional components of the existing sebum membrane to combine with high-family small molecular peptides and a plurality of plant protection raw materials, and the problem that the existing bionic fetal lipid cosmetic is large in coating particle size and difficult to pass through the sebum membrane is effectively solved by utilizing a high-pressure homogenization technology.
(3) The bionic fetal lipid composition disclosed by the invention can be used for effectively removing free radicals generated by blue light irradiation, reducing the damage of the free radicals to skin, simultaneously helping to repair skin damaged by blue light, keeping skin elasticity, resisting skin photoaging, repairing barriers, regulating grease balance and effectively resisting pollution.
Drawings
FIG. 1 is a graph of diffusion contrast experiments of example 1 and comparative example of the present invention;
FIG. 2 is a graph of a comparative experiment of the bionic fetal lipid composition of the invention as a skin care additive.
Detailed Description
The invention will be described in detail below with reference to the drawings and the detailed description.
The bionic fetal fat composition consists of a phase A, a phase B and a phase C, wherein the phase A consists of the following components in parts by mass: 5 to 10 parts of hydrogenated lecithin, 5 to 20 parts of glycerol, 0.1 to 3 parts of biological sugar gum-2, 0.01 to 0.3 part of sodium hyaluronate and 13 to 83 parts of deionized water;
the phase B consists of the following components in parts by mass: 0.5 to 5 parts of ceramide NP, 0.1 to 3 parts of cholesterol, 0.5 to 5 parts of beeswax, 0.3 to 3 parts of stearic acid, 1 to 7 parts of caprylic/capric triglyceride, 1 to 5 parts of squalane, 0.5 to 7 parts of prinsepia utilis royle oil and 0.1 to 1 part of tocopherol,
the phase C consists of the following components in parts by mass: 0.005-0.1 part of superoxide dismutase, 0.0005-0.002 part of tripeptide-1 copper, 0.3-2.5 parts of kava extract, 0.5-4 parts of capsicum extract, 0.1-3 parts of tequila leaf extract and 2-8 parts of dipyrus fermentation lysate.
The mass ratio of the phase A to the phase B to the phase C is: and B phase: phase c=20 to 95:3.5 to 40:2.5 to 20.
The prinsepia utilis royle oil and the components of the sebaceous membrane, namely the ceramide, the cholesterol and the fatty acid are selected for preparation, and the natural fatty acid content of the prinsepia utilis royle oil is balanced, so that the repairing effect of the skin barrier can be well enhanced by matching the prinsepia utilis royle oil with the components of the ceramide, the cholesterol and the fatty acid, and the resistance of the skin is enhanced.
The preparation method of the bionic fetal fat composition is specifically implemented according to the following steps:
step 1, respectively weighing hydrogenated lecithin, glycerol, biological sugar gum-2, sodium hyaluronate, deionized water, ceramide NP, cholesterol, beeswax, stearic acid, caprylic/capric triglyceride, squalane, prinsepia utilis royle oil, tocopherol, superoxide dismutase, tripeptide-1 copper, kava extract, capsicum extract, tequila extract and a schizosaccharomyces cerevisiae fermentation lysate according to the mass parts to form A, B, C phases respectively; and the mass ratio A phase: and B phase: phase c=20 to 95:3.5 to 40:2.5 to 20.
Step 2, adding the phase A obtained in the step 1 into an emulsifying pot, stirring the liquid in the pot at a rotating speed of 30-50 r/min, heating the liquid in the emulsifying pot to 80-85 ℃ at the same time, homogenizing for 2-5 min when the liquid is heated to a set temperature, regulating the temperature of the liquid to 78-82 ℃, and continuously stirring at a rotating speed of 30-50 r/min for 10-15 min until the liquid is free of granular or powder precipitation and suspension, so that the phase A is completely dissolved;
adding the phase B obtained in the step 1 into an oil phase pot, stirring the liquid in the pot at a rotating speed of 30-50 r/min, heating the liquid in the oil phase pot to 80-85 ℃ at the same time, then keeping the temperature of the liquid at 80-85 ℃, and continuing stirring at the rotating speed of 30-50 r/min for 10-30 min until the liquid is granular or powder-free to precipitate and suspend, so that the phase B is completely dissolved;
step 3, when the liquid in the emulsifying pot in the step 2 is homogenized, adding the liquid in the oil phase pot into the emulsifying pot, homogenizing the mixed solution for 5-10 min in a vacuum state, stirring at a rotating speed of 30-50 r/min for 10-20 min, and cooling the mixed liquid to 40-50 ℃;
and 4, cooling the liquid prepared in the step 3 to a set temperature, adding the phase C into an emulsifying pot, stirring for 20-30 min at a stirring speed of 20-40 r/min, completely homogenizing, then delivering into a high-pressure fluid nano homogenizer for treatment, setting the pressure of the high-pressure fluid nano homogenizer to be 1100-1300 psi, and performing cyclic treatment on the solution for 6-10 times until the particle size is reduced by 7-10 times, thus obtaining the bionic fetal fat composition.
The preparation method of the invention effectively solves the problems that the existing bionic fetal lipid cosmetic has large coating particle size and is difficult to pass through sebum membranes by utilizing a high-pressure homogenization technology.
The bionic fetal fat composition is applied as a skin care product additive.
When the bionic fetal fat composition prepared by the invention is used as a skin care product additive, the adding proportion accounts for 4-6% of the total mass of the skin care product to be added.
Example 1
Step 1, respectively weighing 5 parts of hydrogenated lecithin, 5 parts of glycerol, 0.1 part of biological gum-2, 0.01 part of sodium hyaluronate and 83 parts of deionized water according to parts by weight, and mixing and uniformly stirring the weighed material components to form a phase A;
according to the parts by weight, respectively weighing 0.5 part of ceramide NP, 0.1 part of cholesterol, 0.5 part of beeswax, 0.3 part of stearic acid, 1 part of caprylic/capric triglyceride, 1 part of squalane, 0.5 part of prinsepia utilis royle oil and 0.1 part of tocopherol, mixing the weighed material components and stirring uniformly to form a phase B;
according to the parts by weight, respectively weighing 0.005 part of superoxide dismutase, 0.0005 part of tripeptide-1 copper, 0.3 part of kava extract, 0.5 part of capsicum extract, 0.1 part of agave leaf extract and 2 parts of bifenthrite yeast fermentation lysate, mixing the weighed material components uniformly, and stirring to form a C phase;
the mass ratio between the phase A, the phase B and the phase C is that: and B phase: phase C = 95:40:20.
Step 2, adding the phase A obtained in the step 1 into an emulsifying pot, stirring the liquid in the pot at a rotating speed of 30r/min, heating the liquid in the emulsifying pot to 80 ℃ at the same time, homogenizing for 2min when the liquid is heated to a set temperature, adjusting the temperature of the liquid to 78 ℃, and continuing stirring at a rotating speed of 30r/min for 15min until the liquid is free of particles or powder precipitation and suspension, so that the phase A is completely dissolved;
adding the phase B into the oil phase pot, stirring the liquid in the pot at a rotating speed of 30r/min, heating the liquid in the oil phase pot to 80 ℃, and then keeping the temperature of the liquid at 80 ℃ and continuously stirring for 30min at a rotating speed of 30r/min until the liquid is granular or powder-free to precipitate and suspend, so that the phase B is completely dissolved;
step 3, when the liquid in the emulsifying pot in the step 2 is homogenized, adding the liquid in the oil phase pot into the emulsifying pot, homogenizing the mixed solution for 5min in a vacuum state, stirring at a rotating speed of 30r/min, stirring for 20min, and cooling the mixed liquid to 40 ℃;
and 4, cooling the liquid prepared in the step 3 to a set temperature, adding the phase C into an emulsifying pot, stirring for 30min at a stirring speed of 20r/min, feeding the solution into a high-pressure fluid nano homogenizer for treatment after the solution is completely uniform, setting the pressure of the high-pressure fluid nano homogenizer to be 1100psi, and circularly treating the solution for 6 until the particle size is reduced by 7 times, thereby obtaining the bionic fetal fat composition.
Example 2
Step 1, respectively weighing 8 parts of hydrogenated lecithin, 12 parts of glycerol, 1.5 parts of biological gum-2, 0.15 part of sodium hyaluronate and 49 parts of deionized water according to parts by weight, and mixing and uniformly stirring the weighed material components to form a phase A;
according to the parts by weight, 2.33 parts of ceramide NP, 1.55 parts of cholesterol, 2.5 parts of beeswax, 1.03 parts of stearic acid, 4 parts of caprylic/capric triglyceride, 3 parts of squalane, 3.5 parts of prinsepia utilis royle oil and 0.5 part of tocopherol are respectively weighed, and the weighed material components are mixed and stirred uniformly to form a phase B;
according to the parts by weight, respectively weighing 0.05 part of superoxide dismutase, 0.001 part of tripeptide-1 copper, 1.2 parts of kava extract, 2.3 parts of capsicum extract, 1.2 parts of agave leaf extract and 6 parts of bifenthrite yeast fermentation lysate, mixing the weighed material components uniformly, and stirring to form a C phase;
the mass ratio between the phase A, the phase B and the phase C is that: and B phase: phase C = 50:20:10.
Step 2, adding the phase A obtained in the step 1 into an emulsifying pot, stirring the liquid in the pot at a rotating speed of 40r/min, heating the liquid in the emulsifying pot to 82 ℃ at the same time, homogenizing for 4min when the liquid is heated to a set temperature, adjusting the temperature of the liquid to 80 ℃, and continuing stirring at a rotating speed of 40r/min for 12min until the liquid is granular or powder-free to precipitate and suspend, so that the phase A is completely dissolved;
adding the phase B into the oil phase pot, stirring the liquid in the pot at a rotating speed of 40r/min, heating the liquid in the oil phase pot to 82 ℃, and then keeping the temperature of the liquid at 82 ℃ and continuously stirring at the rotating speed of 40r/min for 20min until the liquid is granular or powder-free to precipitate and suspend, so that the phase B is completely dissolved;
step 3, when the liquid in the emulsifying pot in the step 2 is homogenized, adding the liquid in the oil phase pot into the emulsifying pot, homogenizing the mixed solution for 8min in a vacuum state, stirring at a rotating speed of 40r/min, stirring for 15min, and cooling the mixed liquid to 45 ℃;
and 4, cooling the liquid prepared in the step 3 to a set temperature, adding the phase C into an emulsifying pot, stirring for 25min at a stirring speed of 30r/min, feeding the solution into a high-pressure fluid nano homogenizer for treatment after the solution is completely uniform, setting the pressure of the high-pressure fluid nano homogenizer to be 1200psi, and circularly treating the solution for 8 times until the particle size is reduced by 8 times, thereby obtaining the bionic fetal fat composition.
Example 3
Step 1, respectively weighing 10 parts of hydrogenated lecithin, 20 parts of glycerol, 3 parts of biological sugar gum-2, 0.3 part of sodium hyaluronate and 13 parts of deionized water according to parts by weight, and mixing and uniformly stirring the weighed material components to form a phase A;
according to the parts by weight, respectively weighing 5 parts of ceramide NP, 3 parts of cholesterol, 5 parts of beeswax, 3 parts of stearic acid, 7 parts of caprylic/capric triglyceride, 5 parts of squalane, 7 parts of prinsepia utilis royle oil and 1 part of tocopherol, mixing the weighed material components and stirring uniformly to form a phase B;
according to the parts by weight, respectively weighing 0.1 part of superoxide dismutase, 0.002 part of tripeptide-1 copper, 2.5 parts of kava extract, 4 parts of capsicum fruit extract, 3 parts of agave-leaf-lack extract and 8 parts of schizosaccharomyces cerevisiae fermentation lysate, mixing the weighed material components and stirring uniformly to form a C phase;
the mass ratio between the phase A, the phase B and the phase C is that: and B phase: phase C = 20:3.5:2.5.
Step 2, adding the phase A obtained in the step 1 into an emulsifying pot, stirring the liquid in the pot at a rotating speed of 50r/min, heating the liquid in the emulsifying pot to 85 ℃, homogenizing for 5min when the liquid is heated to a set temperature, adjusting the temperature of the liquid to 82 ℃, and continuing stirring at a rotating speed of 50r/min for 10min until the liquid is free from granular or powder precipitation and suspension, so that the phase A is completely dissolved;
adding the phase B into the oil phase pot, stirring the liquid in the pot at the rotating speed of 50r/min, heating the liquid in the oil phase pot to 85 ℃, and then keeping the temperature of the liquid at 85 ℃ and continuously stirring for 10min at the rotating speed of 50r/min until the liquid is granular or powder-free to precipitate and suspend, so that the phase B is completely dissolved;
step 3, when the liquid in the emulsifying pot in the step 2 is homogenized, adding the liquid in the oil phase pot into the emulsifying pot, homogenizing the mixed solution for 10min in a vacuum state, stirring at a rotating speed of 50r/min, stirring for 10min, and cooling the mixed liquid to 50 ℃;
and 4, cooling the liquid prepared in the step 3 to a set temperature, adding the phase C into an emulsifying pot, stirring for 20min at a stirring speed of 40r/min, feeding the solution into a high-pressure fluid nano homogenizer for treatment after the solution is completely uniform, setting the pressure of the high-pressure fluid nano homogenizer to be 1300psi, and carrying out cyclic treatment on the solution for 10 times until the particle size is reduced by 10 times, thereby obtaining the bionic fetal fat composition.
Products 1, 2 and 3 were finally prepared according to examples 1 to 3, and the products 1 to 3 were tested for irritation and stability, and the test results are shown in table 1;
TABLE 1 results of products 1, 2 and 3 irritation and stability tests
Note that: 1. stability is the result of testing the sample at 45 ℃ and normal temperature and-18 ℃ under different conditions;
2. mildness is a result of the patch test.
From the examination of products 1, 2 and 3 in Table 1, it can be seen that products 1, 2 and 3 each have good stability, and the precipitation of ceramide can be prevented.
Comparative example
Comparative example based on example 1, the mixed solution was not subjected to high-pressure fluid nanohomogenization at step 4, and the resulting product had no particle size compression.
As shown in fig. 1, the products prepared in example 1 and comparative example were subjected to a water-soluble diffusion test at the same time, and the products prepared in the left comparative example were slowly diffused after being introduced into water, and were in the form of water drops after 5 seconds; the product prepared in the right example 1 is quickly diffused in water, and is completely diffused in water after 5 seconds, so that the bionic fetal lipid composition prepared by the invention is proved to be small in coating particle size and easy to diffuse through the sebum membrane to repair skin barriers by adopting the combination of various nutritional ingredients of the sebum membrane, high-family small molecular peptides and various plant protection raw materials and utilizing a high-pressure homogenization technology.
As shown in fig. 2, the product 2 is selected and added into a certain skin care product, the adding proportion of the product 2 accounts for 5% of the total mass of the skin care product, a comparison experiment is carried out with the same skin care product without the product 2, and the change of the test part is tested for 30 minutes by a professional visual instrument, so that the skin care product added with the product 2 can be used for rapidly relieving skin problems and relieving the skin problems immediately.
Further, 15 persons with serious skin sensitive red areas caused by working or living environments are selected, a test is carried out for 28 days, the skin care product without the product 2 is coated on the left face of the person to be tested, the skin care product with the product 2 is coated on the right face of the person to be tested, data of the tested parts are detected every 14 days, and the detection data are shown in tables 2 and 3.
Table 2 comparison of the repair effect with or without added sample 2
Note that: the lower the skin redness detection value, the smaller the redness.
As can be seen from table 2, 15 testers use the skin care product without product 2 for 28 days, the average skin redness rate of change to the low is 2.87%, and the average skin redness rate of change to the low is 20.37% after using the skin care product with product 2 for 28 days, so that it is verified that the skin care product with product 2 prepared by the invention can effectively repair the skin barrier, and the repairing effect is remarkable, so that the long-term pigmentation and damage of the skin caused by blue light irradiation are effectively relieved.
TABLE 3 skin elasticity comparison with or without added sample 2
Note that: the closer the skin elasticity detection value is to 1, the better the skin elasticity.
From the data in Table 3, it is shown that 15 testers have an average elasticity change rate of 7.61% after 28 days of the left face of the skin care product to which product 2 is not added, and an average elasticity change rate of 16.45% after 28 days of the right face of the skin care product to which product 2 is added, which further demonstrates that the bionic fetal lipid composition prepared by the present invention can repair the protective barrier of skin, thereby significantly improving skin elasticity.
Claims (3)
1. The preparation method of the bionic fetal fat composition is characterized by comprising the following steps of:
step 1, respectively weighing 5-10 parts of hydrogenated lecithin, 5-20 parts of glycerol, 0.1-3 parts of biological sugar gum-2, 0.01-0.3 part of sodium hyaluronate and 13-83 parts of deionized water according to parts by weight, and mixing and uniformly stirring the weighed material components to form a phase A;
according to the parts by weight, respectively weighing 0.5-5 parts of ceramide NP, 0.1-3 parts of cholesterol, 0.5-5 parts of beeswax, 0.3-3 parts of stearic acid, 1-7 parts of caprylic/capric triglyceride, 1-5 parts of squalane, 0.5-7 parts of prinsepia utilis royle oil and 0.1-1 part of tocopherol, mixing and uniformly stirring the weighed material components to form a phase B;
according to the parts by weight, respectively weighing 0.005-0.1 part of superoxide dismutase, 0.0005-0.002 part of tripeptide-1 copper, 0.3-2.5 parts of kava extract, 0.5-4 parts of capsicum extract, 0.1-3 parts of tequila leaf extract and 2-8 parts of schizosaccharomyces cerevisiae fermentation lysate, mixing and stirring the weighed material components uniformly to form a C phase;
the mass ratio among the phase A, the phase B and the phase C is the phase A: and B phase: phase c=20 to 95:3.5 to 40:2.5 to 20;
step 2, adding the phase A obtained in the step 1 into an emulsifying pot, and stirring until the liquid is granular or powder-free to precipitate and suspend, so that the phase A is completely dissolved; adding the phase B obtained in the step 1 into an oil phase pot, and stirring until the liquid is granular or powder-free to precipitate or suspend, so that the phase B is completely dissolved;
the stirring in the step 2 is carried out to dissolve the phase A substance, namely, stirring the liquid in the pot at the rotating speed of 30-50 r/min, heating the liquid in the emulsifying pot to 80-85 ℃ at the same time, homogenizing for 2-5 min, then adjusting the temperature of the liquid to 78-82 ℃, and continuing stirring for 10-15 min at the rotating speed of 30-50 r/min;
stirring in the step 2 to dissolve the B phase substance, namely stirring the liquid in the oil phase pot at a rotating speed of 30-50 r/min, heating the liquid in the oil phase pot to 80-85 ℃, and then keeping the liquid temperature at 80-85 ℃ and continuously stirring at a rotating speed of 30-50 r/min for 10-30 min;
step 3, adding the phase B processed in the step 2 into the emulsifying pot for mixing when the phase A liquid in the emulsifying pot is homogenized in the step 2, homogenizing the mixed solution for 5-10 min under a vacuum state, stirring for 10-20 min, and cooling the mixed liquid;
in the step 3, the stirring rotation speed is 30r/min to 50r/min, and the temperature of the solution after cooling is 40 ℃ to 50 ℃;
step 4, adding the phase C into an emulsifying pot, stirring for 20-30 min at a stirring speed of 20-40 r/min, and after the phase C is completely uniform, sending the phase C into a high-pressure fluid nanometer homogenizer for treatment, thus obtaining a bionic fetal fat composition;
the high-pressure fluid nano homogenizer in the step 4 is specifically to set the pressure of the high-pressure fluid nano homogenizer to be 1100-1300 psi, and the solution is circularly treated for 6-10 times until the particle size is reduced by 7-10 times.
2. The bionic fetal lipid composition prepared by the preparation method according to claim 1 is characterized by comprising an A phase, a B phase and a C phase, wherein the A phase comprises the following components in parts by mass: 5-10 parts of hydrogenated lecithin, 5-20 parts of glycerol, 0.1-3 parts of biological sugar gum-2, 0.01-0.3 part of sodium hyaluronate and 13-83 parts of deionized water;
the phase B consists of the following components in parts by mass: 0.5-5 parts of ceramide NP, 0.1-3 parts of cholesterol, 0.5-5 parts of beeswax, 0.3-3 parts of stearic acid, 1-7 parts of caprylic/capric triglyceride, 1-5 parts of squalane, 0.5-7 parts of prinsepia utilis royle oil and 0.1-1 part of tocopherol;
the phase C consists of the following components in parts by mass: 0.005-0.1 part of superoxide dismutase, 0.0005-0.002 part of tripeptide-1 copper, 0.3-2.5 parts of kava extract, 0.5-4 parts of capsicum extract, 0.1-3 parts of tequila extract, and 2-8 parts of schizosaccharomyces cerevisiae fermentation lysate;
the mass ratio among the phase A, the phase B and the phase C is that the phase A: and B phase: phase c=20 to 95:3.5 to 40:2.5 to 20.
3. Use of the bionic fetal lipid composition of claim 2 as a skin care additive.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211142867.1A CN115501138B (en) | 2022-09-20 | 2022-09-20 | Bionic fetal fat composition, preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211142867.1A CN115501138B (en) | 2022-09-20 | 2022-09-20 | Bionic fetal fat composition, preparation method and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115501138A CN115501138A (en) | 2022-12-23 |
| CN115501138B true CN115501138B (en) | 2023-10-27 |
Family
ID=84503706
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211142867.1A Active CN115501138B (en) | 2022-09-20 | 2022-09-20 | Bionic fetal fat composition, preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115501138B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116747340B (en) * | 2023-08-21 | 2023-11-24 | 露乐健康科技股份有限公司 | Bionic fetal fat composition, paper diaper, preparation method and application of paper diaper |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6541018B1 (en) * | 1998-12-17 | 2003-04-01 | L'oreal | Nanoemulsion based on glycerol fatty esters, and its uses in the cosmetics, dermatological and/or ophthalmological fields |
| CN110960468A (en) * | 2020-01-09 | 2020-04-07 | 伊尔瑞生物科技(江苏)有限公司 | Preparation method of anti-aging and anti-blue-light cosmetic containing plant extract |
| CN111700826A (en) * | 2020-06-19 | 2020-09-25 | 泉后(广州)生物科技研究院有限公司 | Composition for repairing skin barrier and preparation method and application thereof |
| CN113384483A (en) * | 2020-03-10 | 2021-09-14 | 盈妆生物科技(上海)有限公司 | Composition for improving skin elasticity and delaying aging and preparation method thereof |
-
2022
- 2022-09-20 CN CN202211142867.1A patent/CN115501138B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6541018B1 (en) * | 1998-12-17 | 2003-04-01 | L'oreal | Nanoemulsion based on glycerol fatty esters, and its uses in the cosmetics, dermatological and/or ophthalmological fields |
| CN110960468A (en) * | 2020-01-09 | 2020-04-07 | 伊尔瑞生物科技(江苏)有限公司 | Preparation method of anti-aging and anti-blue-light cosmetic containing plant extract |
| CN113384483A (en) * | 2020-03-10 | 2021-09-14 | 盈妆生物科技(上海)有限公司 | Composition for improving skin elasticity and delaying aging and preparation method thereof |
| CN111700826A (en) * | 2020-06-19 | 2020-09-25 | 泉后(广州)生物科技研究院有限公司 | Composition for repairing skin barrier and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115501138A (en) | 2022-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9839605B2 (en) | Borojo skin care product and use thereof for natural moisturizing, anti-ageing, anti-UV, anti-anaphylaxis and whitening | |
| CN107397714A (en) | With anti-blue light contamination and the elite breast of desalination microgroove effect and its preparation and application | |
| CN110755321A (en) | Composition for quick allergy relief and preparation method and application thereof | |
| CN115501138B (en) | Bionic fetal fat composition, preparation method and application | |
| CN106176566A (en) | Cosmetic composition with white-skinned face function and preparation method thereof | |
| CN109464316A (en) | Skin conditioning composition, Medical cold application with antiallergic anti-inflammatory effect and preparation method thereof | |
| CN110237016B (en) | Composition with blue light resisting and repairing effects and preparation method and application thereof | |
| CN107822946A (en) | A kind of painting type water light porcelain flesh Essence and preparation method thereof | |
| CN113117051B (en) | Anti-aging transdermal polypeptide preparation and preparation method thereof | |
| CN109549893A (en) | A kind of preparation method with anti-blue light contamination and the composition repaired and essence cream and its essence cream | |
| US20240108566A1 (en) | Composition containing recombinant collagen with repairing and soothing effects, eye cream containing the composition and preparation method thereor | |
| CN115678805B (en) | Preparation method and application of tricholoma matsutake yeast fermentation liquor with repairing and anti-aging effects | |
| CN107929166A (en) | A kind of pro-skin massage oil and preparation method thereof | |
| CN113768819B (en) | Preparation method of moisturizing and anti-aging cosmetic composition containing cationic hyaluronic acid | |
| CN109498543A (en) | The composition of adjustable skin microecological balance and its application and comprising its milky lotion and milky lotion preparation method | |
| CN110464672A (en) | A kind of cosmetic composition with safe antioxidant effect | |
| CN108635326A (en) | Anti-aging and wrinkle-removing composition containing dendrobium stem cell extract and application thereof | |
| CN112353722A (en) | Moisturizing anti-aging repairing composition and preparation method and application thereof | |
| CN111728889A (en) | A composition containing curcumin, ectoin and madecassoside with synergistic antiinflammatory effect, and its application | |
| CN116327674A (en) | Anti-wrinkle compact micro-nano essence emulsion and preparation method thereof | |
| CN107184543B (en) | Skin-care substrate with acne-inhibiting and acne-removing effects and preparation method and application thereof | |
| CN111743798B (en) | Multi-effect anti-aging skin care product and preparation method thereof | |
| CN106937918A (en) | A kind of natural radiation-preventing composition and its application | |
| CN114366698B (en) | Anti-aging composition, preparation method thereof and application thereof in cosmetics | |
| CN110090181A (en) | A kind of preparation method and applications of linseed emulsifier |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |